Polymerase Chain Reaction Market Research Report: Information By Product (Instruments, Reagents and Consumables, and Software), Application (Clinical Diagnostics, Life Science Research, Industrial Applications, and Other Applications), End User (Academic Institutes, Clinical Diagnostics Labs and Hospitals, Pharmaceutical and Biotechnology Industries, and Other End Users), And By Region (North America, Europe, Asia-Pacific, And Rest of The World) –Market Forecast Till 2032.

Global Polymerase Chain Reaction Market Overview

Polymerase Chain Reaction Market Size was valued at USD 13.2 Billion in 2022. The Polymerase Chain Reaction Market industry is projected to grow from USD 14.3 Billion in 2023 to USD 27.50 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.50% during the forecast period (2023 - 2032).  The Increasing demand for advanced diagnostic techniques, the rising number of CROs, forensic & research laboratories, prenatal genetic testing procedures, and the launch of novel technologies are expected to be significant market drivers for the Polymerase Chain Reaction Market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Polymerase Chain Reaction Market Trends

Rising demand for personalized and precision medicine and an increase in the prevalence of chronic and infectious diseases are driving the market growth

Market CAGR for Polymerase Chain Reaction is driven by the rising demand for personalized and precision medicine and the increase in the prevalence of chronic diseases and infectious diseases. The polymerase chain reaction market is experiencing significant growth, primarily driven by the increasing demand for personalized and precision medicine. A January 2022 article published by PubMed Central highlighted the rapid evolution of personalized medicine (PM), expanding its application beyond genomics to integrate various data, such as daily health, disease characteristics, organ function, environmental factors, and lifetime exposure. Additionally, a September 2022 article from PubMed emphasized the emergence of digital PCR (dPCR) as a technology offering higher precision and improved indicators compared to traditional PCR techniques. This technological advancement, especially in dPCR, is well-suited for precision medicine applications requiring accurate molecular characterization with high sensitivity, contributing to the rising adoption of PCR in this field and subsequently boosting market growth.

The increase in the prevalence of chronic and infectious diseases and genetic disorders is expected to boost the demand. As per the CDC, chronic illnesses such as cancer, diabetes, and respiratory diseases like asthma contribute to 7 in 10 deaths annually in the U.S. Additionally, the growing number of individuals affected by congenital heart disease necessitates the exploration of molecular diagnostic tools for accurate diagnoses. The CDC notes that congenital heart defects are the most common birth defects in the U.S., impacting around 1% of births annually. Consequently, the increasing incidence of diseases is fostering a heightened demand for innovative molecular diagnostic tests in the forecast period. As a result, it is anticipated that throughout the projection period, demand for the Polymerase Chain Reaction Market will increase due to the rising demand for personalized and precision medicine, and an increase in the prevalence of chronic and infectious diseases. Thus, driving the Polymerase Chain Reaction Market revenue.

Polymerase Chain Reaction Market Segment Insights

Polymerase Chain Reaction Market Product Insights

The Polymerase Chain Reaction Market segmentation, based on Product includes Instruments, Reagents and Consumables, and Software. The Reagents and Consumables segment dominated the market, accounting for 58% of market revenue (7.6 Billion). The segment encompassing reagents and consumables also involves assay reagents for endpoint detection. The growth of the PCR reagents and consumables market will be fueled by the expanding applications of dPCR, a rising number of dPCR-based analytical procedures among institutional researchers (including CROs and pharma-biotech companies), and the increasing   availability of innovative dPCR reagents. Moreover, the broadening application scope of dPCR technology in genetic/molecular research, clinical diagnosis, and forensics is anticipated to lead to the commercial introduction of novel dPCR reagents. Notably, Bio-Rad Laboratories introduced the QXDx BCR-ABL %IS Kit in 2019, and in 2022, Fluidigm Corporation unveiled the X9 Real-Time PCR System, a cutting-edge and versatile high-capacity genomics platform.

Figure 1:   Polymerase Chain Reaction Market, by Product, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Polymerase Chain Reaction Market Application Insights

The Polymerase Chain Reaction Market segmentation, based on Application includes Clinical Diagnostics, Life Science Research, Industrial Applications, and Other Applications. The Clinical Diagnostics segment dominated the market, accounting for 58% of market revenue (7.6 Billion). The anticipated increase in the prevalence of infectious diseases is poised to boost the growth of this market segment. For example, according to UNAIDS data from 2022, approximately 38.4 million individuals worldwide were living with HIV in 2021, and 1.5 million new HIV infections occurred in the same year. Consequently, the   upswing in infectious diseases is expected to amplify the expansion of this segment, given the crucial role that PCR plays in disease diagnosis. Furthermore, the introduction of new products is contributing to the growth of this market segment. A case in point is the August 2022 launch of Molbio Diagnostics' Trunet RT-PCR test, designed for the rapid and differential diagnosis of HIV-1 and HIV-2 with viral load determination within 60 minutes. Such product launches are instrumental in propelling the advancement of the market segment.

Polymerase Chain Reaction Market End-User Insights

The Polymerase Chain Reaction Market segmentation, based on End-User includes Academic Institutes, Clinical Diagnostics Labs and Hospitals, Pharmaceutical and Biotechnology Industries, and Other End Users. The Clinical Diagnostics Labs and Hospitals segment dominated the market, accounting for 60% of market revenue (7.9 billion). PCR technologies play a crucial role in hospitals and diagnostic centers for activities such as viral load testing, genetic testing, profiling of embryo DNA before in vitro fertilization, and organ/tissue transplant procedures. The growth of this end-user segment is driven by factors such as the increased market availability of qPCR reagents, expansion of healthcare infrastructure in emerging markets, high prevalence of target diseases, and growing awareness among end users about the rapid and effective disease diagnosis benefits offered by qPCR.

Polymerase Chain Reaction Market Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Polymerase Chain Reaction market in North America can be attributed to several key factors. The market is poised for substantial growth, primarily driven by the introduction of new products based on PCR tests. A notable example is Roche's launch of the Cobas 5800 System in the United States in November 2022. This compact, fully automated molecular laboratory instrument provides a flexible PCR testing solution, assisting clinicians in diagnosing infectious diseases. Additionally, in May 2021, the TheraScreen KRAS RGQ PCR Kit by Qiagen received approval from the United States FDA. This laboratory test detects seven mutations in the KRAS gene associated with non-small cell lung cancer and colorectal cancer. Considering factors such as the increasing prevalence of genetic and chronic disorders, coupled with the ongoing release of innovative PCR test-based products, the market is anticipated to experience substantial growth in the region throughout the forecast period.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2:   POLYMERASE CHAIN REACTION MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Polymerase Chain Reaction Market accounts for the second-largest market share as the surge in the development of pharmaceuticals is a key driver behind the growth of the Polymerase Chain Reaction (PCR) market in Europe, fueled by the substantial burden of infectious diseases in the region. Notably, the prevalence of sexually transmitted infections (STIs) poses a significant public health challenge in the United Kingdom. As of December 2021, government data indicated 311,604 new STI diagnoses among England residents, representing a marginal increase of 0.5% from the 2020 figures (309,921). However, there was a notable decrease of 33.2% compared to 2019. Chlamydia emerged as the most commonly diagnosed STI, accounting for 51% of all new cases (161,672), followed by first-episode genital warts (27,473; 9%), gonorrhea (57,084; 18%), and genital herpes (20,530; 6%). This rise in the prevalence of infectious diseases, particularly STIs, is anticipated to be a significant driving force behind the growth of the PCR market in the forecast period. Further, the German Polymerase Chain Reaction Market held the largest market share, and the UK Polymerase Chain Reaction Market was the fastest-growing market in the European region.

The Asia-Pacific Polymerase Chain Reaction Market is expected to grow at the fastest CAGR from 2023 to 2032. The Asia Pacific region has witnessed substantial growth in healthcare spending due to factors such as sustained economic expansion in multiple countries and rising disposable income levels among the middle-class population. Furthermore, the modernization of healthcare infrastructure, the widespread adoption of advanced diagnostic technologies like dPCR and qPCR for both research and clinical purposes, increasing awareness among healthcare professionals regarding the advantages of gene-based disease diagnosis and treatment, and rising public-private collaborations to innovate PCR technologies are anticipated to bolster market growth in the Asia Pacific region throughout the forecast period. Moreover, China’s Polymerase Chain Reaction Market held the largest market share, and the Indian Polymerase Chain Reaction Market was the fastest-growing market in the Asia-Pacific region.

Polymerase Chain Reaction Market Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the Polymerase Chain Reaction market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their   footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Polymerase Chain Reaction industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Polymerase Chain Reaction industry to benefit clients and increase the market sector. In recent years, the Polymerase Chain Reaction industry has offered some of the most significant advantages to scientific research, diagnostics, and medical advancements. Major players in the Polymerase Chain Reaction Market, including Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc., GE Healthcare, Merck KGaA, PerkinElmer Inc., Promega Corporation, Siemens Healthcare, and Thermo Fisher Scientific Inc are attempting to increase market demand by investing in research and development operations.

Thermo Fisher Scientific Inc (Thermo Fisher) is a company that specializes in providing medical equipment, analytical instruments, reagents, consumables, software, and services to address complex analytical challenges in research, diagnostics, and clinical laboratories. Their offerings include solutions for cellular analysis, biology, flow cytometry, and synthetic biology. Thermo Fisher has a diverse product range encompassing technologies for mass spectrometry, genetic sequencing, electron microscopy, as well as protein and molecular biology research. The company caters to pharmaceutical and biotech firms, academic and research institutions, clinical diagnostic labs, government agencies, and sectors related to environmental, industrial quality, and process control. Sales of its products and services are conducted through a direct sales force, e-commerce, and third-party distributors across the Americas, Asia-Pacific, and Europe. Thermo Fisher is headquartered in Waltham, Massachusetts, USA. In October 2021, the company introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, a groundbreaking fully integrated digital PCR (dPCR) system designed to deliver highly accurate and consistent genetic analysis results within a 90-minute timeframe.

Agilent Technologies, Inc. (Agilent) is a leading provider of analytical instruments, reagents, and consumables designed for laboratory processes. The company also offers complementary software and services, with a primary focus on scientific research, patient diagnostics, and safety testing in areas such as water, food, and pharmaceuticals. Agilent's extensive product portfolio includes mass spectrometry, microarray solutions, flow cytometry, vacuum technologies, and more. Serving diverse industries including contract research organizations (CROs), contract manufacturing organizations (CMOs), pharmaceuticals, diagnostics, applied materials, and chemicals, Agilent has a   presence with sales offices, logistics centers, research and development facilities, and business operations worldwide. The company distributes its products through various channels, including direct sales agents, distributors, resellers, manufacturers' representatives, and electronic commerce. Agilent is headquartered in Santa Clara, California, USA. In March 2021, Agilent Technologies Inc. announced the release of a real-time reverse transcription (qRT) PCR-based diagnostic kit designed for the detection of SARS-CoV-2 RNA. The kit has obtained the CE-IVD mark, aligning with the European Union In-Vitro Diagnostic Directive 98/79/EC, and is readily available for distribution.

Key companies in the Polymerase Chain Reaction Market include

• Abbott Laboratories


• Agilent Technologies Inc


• Becton


• Dickinson and Company


• BioMerieux SA


• Bio-Rad Laboratories Inc


• GE Healthcare


• Merck KGaA


• PerkinElmer Inc


• Promega Corporation


• Siemens Healthcare


• Thermo Fisher Scientific Inc

Polymerase Chain Reaction Industry Developments

November 2022:In November 2022, Cepheid introduced the Xpert Xpress MVP, a multiplexed PCR test capable of detecting DNA from organisms linked to three specific conditions—bacterial vaginosis (BV), vulvovaginal candidiasis, and trichomoniasis. This innovative test allows for the identification of multiple infections from a single sample, enhancing precision in diagnosis and facilitating more accurate antibiotic treatment regimens.

November 2022:In November 2022, PCR Biosystems unveiled a new series of qPCR reagent mixes, namely the Clara Probe Mix, Clara Probe 1-Step Mix, and Clara HRM Mix

Polymerase Chain Reaction Market Segmentation

Polymerase Chain Reaction Market Product Outlook

• Instruments


• Reagents and Consumables


• Software

Polymerase Chain Reaction Market Application Outlook

• Clinical Diagnostics


• Life Science Research


• Industrial Applications


• Other Applications

Polymerase Chain Reaction Market End-User Outlook

• Academic Institutes


• Clinical Diagnostics Labs and Hospitals


• Pharmaceutical and Biotechnology Industries


• Other End Users

Polymerase Chain Reaction Market Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America